FRX Insider Trading

Insider Ownership Percentage: 17.32%
Insider Buying (Last 12 Months): C$0.00
Insider Selling (Last 12 Months): C$33,213.50

Fennec Pharmaceuticals Insider Trading History Chart

This chart shows the insider buying and selling history at Fennec Pharmaceuticals by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Fennec Pharmaceuticals Share Price & Price History

Current Price: C$10.12
Price Change: Price Increase of +0.43 (4.44%)
As of 09/29/2023 01:00 AM ET

This chart shows the closing price history over time for FRX up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
Days: 30 | 90 | 365

Fennec Pharmaceuticals Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
4/28/2023Chris Anigeron RallisDirectorSell916C$8.34C$7,639.44
11/17/2022Chris Anigeron RallisDirectorSell333C$10.63C$3,538.6930,018
10/20/2022Chris Anigeron RallisDirectorSell2,068C$10.66C$22,035.3725,589
9/21/2022Robert Christopher AndradeSenior OfficerSell19,052C$11.02C$209,888.26176,721
9/12/2022Rostislav Christov RaykovDirectorSell16,666C$0.93C$15,479.3821,081,996
7/18/2022Chris Anigeron RallisDirectorBuy11,111C$0.59C$6,499.9432,036
See Full Table
Free Stock Analysis Report: See The True Value of Any Stock
Get a full report that tells you what a stock is really worth, how safe the stock is, and if the timing is right to buy the stock. Plus a definitive Buy, Sell, Hold recommendation.
Analyze Any Stock Free

SEC Filings (Institutional Ownership Changes) for Fennec Pharmaceuticals (TSE:FRX)

50.66% of Fennec Pharmaceuticals stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Fennec Pharmaceuticals logo
Fennec Pharmaceuticals Inc. operates as a biopharmaceutical company. The company's product candidates include PEDMARK, a formulation of sodium thiosulfate for the prevention of platinum-induced ototoxicity hearing loss in pediatric cancer patients. It sells its products through regional pediatric oncology specialists and medical science liaisons. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec Pharmaceuticals Inc. in September 2014. Fennec Pharmaceuticals Inc. was incorporated in 1996 and is based in Research Triangle Park, North Carolina.
Read More on Fennec Pharmaceuticals

Today's Range

Now: C$10.12
Low: C$9.94
High: C$10.12

50 Day Range

MA: C$10.70
Low: C$9.59
High: C$11.27

52 Week Range

Now: C$10.12
Low: C$9.59
High: C$14.41


300 shs

Average Volume

678 shs

Market Capitalization

C$268.89 million

P/E Ratio


Dividend Yield




Who are the company insiders with the largest holdings of Fennec Pharmaceuticals?

Fennec Pharmaceuticals' top insider shareholders include:
  1. Rostislav Christov Raykov (Director)
  2. Robert Christopher Andrade (Senior Officer)
  3. Chris Anigeron Rallis (Director)
Learn More about top insider investors at Fennec Pharmaceuticals.